Copy of APP Podcast Playlist

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021)

CME Available: https://auau.auanet.org/node/31450

ACKNOWLEDGEMENTS
Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:
1. Explain the mechanism of checkpoint inhibitors.
2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.

AUA2021 Kick Off Weekend: Chemotherapy and Immunotherapy for the Urologist and APP

Urolithiasis: Metabolic Evaluation and Medical Management

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: auau.auanet.org/node/31819

At the conclusion of this educational series, participants will be able to:
1. Discuss the impact of SDM on patients and on patient-clinician communication.
2. Identify at least one implementation strategy for using SDM in clinical practice.
3. Apply SDM techniques in a role-playing exercise with other colleagues.
4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.
5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.

Improving Racial Disparities in Treatment Outcomes Podcast

NMIBC Guidelines

CME Available: https://auau.auanet.org/node/33093

At the conclusion of the activity, participants will be able to:
1. Describe recent developments in the medical management of advanced prostate cancer.
2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.
3. Discuss clinical investigations in the treatment of advanced prostate cancer.
4. Analyze the risks and benefits of treatment for advanced prostate cancer.
5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

Acknowledgements
This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.

Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)

CME Available: https://auau.auanet.org/node/33094

Acknowledgements
This educational activity is supported by an independent educational grant from:
Urovant

Live from AUA2021: Highlights in Overactive Bladder (2021)

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS
Co-Host: Sean Elliott, MD

Outline:
1. Are the terms “transitional urology” and “adult congenital urology” synonymous
2. What are the unique challenges in transitional urology
3. Why does spina bifida seem to dominate the transitional urology landscape
4. Exstrophy
5. Counseling pregnant women with a congenital urological condition
6. How does posterior urethral valve bladder present in adulthood

Core Curriculum: Transitional Urology

The AUAUniversity podcast is an official podcast of the American Urological Association.  More information can be found at https://auau.auanet.org

AUA2021 Kick Off Weekend: Chemotherapy and Immunotherapy for the Urologist and APP

AUAUniversity

Related tracks